ORCID as entered in ROS

Select Publications
2025, 'Prognostic significance and accuracy of oncologists’ estimates of survival time in recurrent ovarian cancer', in International Journal of Gynecological Cancer, Vol. 35, http://dx.doi.org/10.1016/j.ijgc.2024.100030
,2024, 'Overall survival and patterns of care for women with rare ovarian cancers: A prospective study from the Australian National Gynae-Oncology Registry (NGOR)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 42, presented at Special Clinical Science Symposia, ELECTR NETWORK, 29 May 2024 - 29 May 2024
,2024, 'Use of cell-free DNA from ascites to identify variants and tumour evolution in a cohort of patients with advanced ovarian cancer', in Journal of Clinical Oncology, American Society of Clinical Oncology, Vol. 42, presented at 2024 ASCO Annual Meeting, 29 May 2024 - 29 May 2024, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.5547
,2024, 'Rates of paclitaxel hypersensitivity reactions using a modified Markman’s infusion protocol as primary prophylaxis', in Supportive Care in Cancer, Vol. 32, http://dx.doi.org/10.1007/s00520-024-08460-z
,2022, 'Dose intensity and outcomes of VDC/IE chemotherapy for adolescent and adult patients with Ewing’s family sarcoma.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 11570 - 11570, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.11570
,2022, 'IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5515 - 5515, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5515
,2022, 'Staging locally advanced cervical cancer with FIGO 2018 versus FIGO 2008: Impact on overall survival and progression-free survival in the OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5531 - 5531, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5531
,2022, 'Rates of somatic variants in homologous recombination DNA repair deficiency genes in older patients with high-grade serous ovarian carcinoma', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 30 - 30
,2021, 'Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 04 June 2021 - 08 June 2021, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.5584
,2019, 'SOLACE2: A phase II randomised trial of immune priming by olaparib-cyclophosphamide prior to olaparib-durvalumab in asymptomatic, platinum-sensitive recurrent ovarian cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 160 - 161, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400250&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,